Neuraxis (NRXS) Receivables - Other (2022 - 2026)
Neuraxis (NRXS) posted Receivables - Other of $528799.0 for Q1 2026, down 23.66% sequentially from $692683.0 in Q4 2025, and up 165.53% YoY from $199145.0 in Q1 2025.
Neuraxis (NRXS) Receivables - Other (2022 - 2026) Analysis & Trends
Neuraxis has reported Receivables - Other for 5 years, with the latest figure at $528799.0 in Q1 2026.
- Quarterly Receivables - Other rose 165.53% year-over-year to $528799.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $528799.0 (up 165.53% YoY) and the FY2025 annual result came in at $692683.0, up 634.16% from the prior year.
- Receivables - Other slipped to $528799.0 in Q1 2026 per NRXS's latest filing, from $692683.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $692683.0 in Q4 2025 and troughed at $70938.0 in Q4 2023.
- A 5-year average of $275655.3 and a median of $178114.0 in 2024 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2023 and 2025: Receivables - Other decreased 24.54% in 2023, then jumped 634.16% in 2025.
- Over 5 years, Receivables - Other stood at $94007.0 in 2022, then fell by 24.54% to $70938.0 in 2023, then jumped by 33.0% to $94351.0 in 2024, then surged by 634.16% to $692683.0 in 2025, then dropped by 23.66% to $528799.0 in 2026.
- According to Business Quant data, Receivables - Other over the past three periods registered $528799.0, $692683.0, and $562500.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 358,975.00 |
| Jun 30, 2026 | 358,975.00 |
| Mar 31, 2026 | 528,799.00 |
| Mar 31, 2026 | 528,799.00 |
| Dec 31, 2025 | 692,683.00 |
| Dec 31, 2025 | 692,683.00 |
| Sep 30, 2025 | 562,500.00 |
| Sep 30, 2025 | 562,500.00 |
| Jun 30, 2025 | 375,000.00 |
| Jun 30, 2025 | 375,000.00 |
| Mar 31, 2025 | 199,145.00 |
| Mar 31, 2025 | 199,145.00 |
| Dec 31, 2024 | 94,351.00 |
| Dec 31, 2024 | 94,351.00 |
| Sep 30, 2024 | 178,114.00 |
| Sep 30, 2024 | 178,114.00 |
| Jun 30, 2024 | 83,042.00 |
| Jun 30, 2024 | 83,042.00 |
| Mar 31, 2024 | 153,629.00 |
| Mar 31, 2024 | 153,629.00 |